modelClioquinol
Extends from Pharmacolibrary.Drugs.ATC.G.G01AC02.
Information
| name: | Clioquinol | |
| ATC code: | G01AC02 | route: | oral |
| compartments: | 1 | |
| dosage: | 250 | mg |
| volume of distribution: | 1.5 | L |
| clearance: | 0.7 | L/h/kg |
| other parameters in model implementation | ||
Clioquinol is a halogenated hydroxyquinoline previously used as an antifungal and antiprotozoal agent, primarily in the treatment of infections such as amoebiasis and some dermatological conditions. Its use as a systemic agent has greatly declined due to safety concerns, but it may still be found in some topical formulations.
Pharmacokinetics
No robust or specific population pharmacokinetic parameters for clioquinol could be found in the primary literature for any population or condition. The following are estimated parameters based on limited historical data, approximate values, and general knowledge of related hydroxyquinolines.
References
Schimmer, AD, et al., & Minden, MD (2012). A phase I study of the metal ionophore clioquinol in patients with advanced hematologic malignancies. Clinical lymphoma, myeloma & leukemia 12(5) 330–336. DOI:10.1016/j.clml.2012.05.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22683301
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)